Aptus Pharma Plans Aggressive Growth Phase with Capital Raise, Targeting Manufacturing and Pan-India Expansion

Aptus Pharma Plans Aggressive Growth Phase with Capital Raise, Targeting Manufacturing and Pan-India Expansion​

Ahmedabad, August 24, 2026: Aptus Pharma Limited, a company currently operating a marketing-led pharmaceutical business model, has outlined a major growth phase. The company plans to strengthen its market presence, expand across India, and explore opportunities in international markets, backed by a proposed preferential issue of equity shares.

The Board of Directors approved a proposal to raise ₹44.88 crore through a preferential equity issue aimed at identified investors. This proposal is subject to the approval of the members at the upcoming Annual General Meeting, scheduled for September 14, 2026, and other requisite statutory and regulatory clearances.

The funds raised are scheduled to be utilized within 36 months from the receipt of the funds. The utilization plan covers capital expenditure, working capital requirements, and general corporate purposes.


The capital expenditure of ₹25 crore is allocated to land acquisition, the manufacturing plant structure, hi-tech storage facilities, and the purchase of vehicles.

Strategic Focus on Manufacturing and Market Reach​

Central to the company’s long-term strategy is the development of internal manufacturing capabilities. Aptus Pharma aims to meet approximately 20% of its product requirements through in-house manufacturing. This move is expected to enhance control over product quality, supply-chain management, and product availability, while supporting the development of its own brand portfolio.

On the domestic front, the company intends to progressively strengthen its sales and distribution network across West, Central, East, and South India to achieve broader Pan-India operations.

Furthermore, Aptus Pharma intends to explore opportunities in select international markets. Potential avenues for international expansion include Africa, the Middle East, and Latin America through product registrations, export partnerships, and other permissible business arrangements.

Managing Director Highlights Strategic Shift​

Tejash Hathi, Managing Director of Aptus Pharma Limited, stated that the company's next phase is focused on evolving into a stronger and more integrated pharmaceutical enterprise.

"Our strategic direction is clear: transitioning from marketing-led operations toward manufacturing capabilities, moving from a regional presence toward Pan-India operations, and from domestic markets toward suitable international opportunities," Mr. Hathi said.

He added that the proposed ₹44.88 crore preferential issue is anticipated to bolster the capital base, support capital expenditure, meet working capital needs, and drive long-term business growth.

The proposed capital raise, combined with the development of manufacturing capabilities, the strengthening of domestic operations, and the exploration of international markets, marks a significant phase in the company's long-term business development.

Stock Price Movement​

Aptus Pharma Ltd is ticking up, currently trading at ₹296.40 after climbing 2.00% as of 10:14 AM. The shares are locked in place this morning, holding completely flat with the intraday high and low both set at ₹296.40.